Zum Hauptinhalt springen

Hepatitiden

18. August 2019 | Hepatitiden

Hepatitis C virus infection status and associated factors among a multi-site sample of people who used illicit drugs in the Amazon region.

Hepatitis C virus infection status and associated factors among a multi-site sample of people who used illicit drugs in the Amazon region. Oliveira-Filho AB, Santos FJA, Silva FQ, Raiol NC, Costa CCS, Piauiense JNF, Martins LC, Cardoso YMN, Di Mice…

18. August 2019 | Hepatitiden

Biomarkers vs imaging in the early detection of hepatocellular carcinoma and prognosis.

Biomarkers vs imaging in the early detection of hepatocellular carcinoma and prognosis. Balaceanu LA. World J Clin Cases. 2019 Jun 26;7(12):1367-1382. doi: 10.12998/wjcc.v7.i12.1367. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656675/

16. August 2019 | Hepatitiden

Good practice examples of hepatitis C prevention, testing and treatment by harm reduction services in Europe.

Good practice examples of hepatitis C prevention, testing and treatment by harm reduction services in Europe. Schatz, E., Perez Gayo, R., & Raulet, I. (2019), Correlation European Harm Reduction Network, Amsterdam. https://www.correlati…

16. August 2019 | Hepatitiden

Hepatitis C interventions by organizations providing Harm reduction services in Europe – analysis and examples.

Hepatitis C interventions by organizations providing Harm reduction services in Europe – analysis and examples. Schatz, E., Perez Gayo, R., & Raulet, I. (2019), Correlation European Harm Reduction Network, Amsterdam. https://www.correla…

12. August 2019 | Hepatitiden

Incidence, prevalence and risk factors for hepatitis C in Danish prisons.

Incidence, prevalence and risk factors for hepatitis C in Danish prisons. Søholm J, Holm DK, Mössner B, Madsen LW, Hansen JF, Weis N, et al. (2019) PLoS ONE 14(7): e0220297. doi.org/10.1371/journal.pone.0220297 https://journals.plos.org/plo…

11. August 2019 | Hepatitiden

Hepatologie: Patienten mit Progressionsrisiko identifizieren und therapieren

Hepatologie: Patienten mit Progressionsrisiko identifizieren und therapieren Warpakowski, Andrea Dtsch Arztebl 2019; 116(31-32): A-1433 / B-1188 / C-1172 Die Schwerpunkthemen der International Liver Conference haben sich verändert: Nicht mehr die…

11. August 2019 | Hepatitiden

Effect of voluntary licences for hepatitis C medicines on access to treatment: a difference-in-differences analysis

Effect of voluntary licences for hepatitis C medicines on access to treatment: a difference-in-differences analysis Simmons, Bryony et al. The Lancet Global Health, Volume 7, Issue 9, e1189 - e1196 https://www.thelancet.com/journals/langlo/…

Weitere Beiträge ansehen

Weitere
akutelle Informationen
zu den Themengebieten